New immunosuppressive treatment in kidney transplantation

Clinical Nephrology

Volumn 53, Issue 4, 2000, Pages 23-32

  Di Landro, D ^a   Sarzo, G ^b   Marchini, F ^c  

^a Ospedale di Monselice   (Italy)

^b Clinica Chirurgica II   (Italy)

^c Divisione Nefrologia II e Dialisi   (Italy)

Author keywords

Clinical outcome; Immunobiology; Immunosuppressive drugs; Kidney transplantation

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CLINICAL PRACTICE; CONFERENCE PAPER; CREATININE CLEARANCE; FEMALE; GRAFT INFECTION; GRAFT SURVIVAL; HUMAN; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0034115167     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (111)

1. Abe M, Sannomiya A, Koike S, Sato S, Sageshima J, Katajima K, Tojimabara T et al 1998 Removal of anti-donor antibody by double filtration plasmapheresis to prevent chronic rejection in kidney transplantation. Transplant Proc 30: 3108-3109
2. Amemiya H, Japanese Collaborative Transplant Study Group of NKT-01 1995 Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Transplant Proc 27: 31-32
3. Bachetoni A, Cinti P, Sallusto F, Poli L, Petragostini R, Alfani D, Renna Malajoni E, Cortesini R 1991 Immunological studies of renal allograft recipients treated with total lymphoid irradiation. Allergol Immunopathol (Madr) 19: 69-77
4. Banowsky LH 1976 The role of adjuvant operations in renal transplantation. Urol Clin North Am 3: 527-551
5. Benigni A, Remuzzi G 1996 Glomerular protein trafficking and progression of renal disease to terminal proteinuria. Semin Nephrol 16: 151-159
6. Berndt WO 1998 The role of transport in chemical nephrotoxicity. Toxicol Pathol 26: 52-57
7. Boeckh M, Biovin G 1998 Quantitaten of cytomegalo-virus: methodologic aspects and clinical applications. Clin Microbiol Rev 11: 533-554
8. Borel JF, Fearer C, Gublier HV, Stahelm H 1976 Biological effects of cyclosporin A: a new antilymphocyte agent. Agents Actions 6: 486
9. Borel JF, Feurer C, Gublier HV, Stahelm H 1977 Effect of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32: 1017-1025
10. Brockmeyer C, Ulbrecht M, Schendel D, Weiss E, Hillebrabd G, Burkardt K, Land W et al 1993 Distribution of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in renal tissue during allograft rejection. Transplantation 55: 610-615
11. Budach W, Classen J, Belka C, Bamberg M 1998 Clinical impact of predictive assays for acute and late radiation morbidity. Strahlenther Onkol 174: 20-24
12. Calvin R 1990 Cellular and molecular mechanisms of allograft rejection. Annu Rev Med 41: 361-375
13. Carson JL, Altmann DG, Duff A, Noveck H, Weinstein MP, Sonnenberg FA, Hudson JI, Provenzano G 1999 Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 39: 694-700
14. Catalano C, Fabbian F, Bordin V, Di Landro D 1997 Mycophenolate mofetil toxicity in an anorexic transplant patient treated with sulphinpirazone. Nephrol Dial Transplant 12: 267-268
15. Christiaans MHL, van Hoff JP, Nieman F, van der Berg-Loonen E 1999 HLA-DR matched transfusions. Transplantation 67: 1029-1035
16. Cicciarelli J, Helstab K, Mendez R 1992 Flow cytometry PRA, a new test that is highly correlated with graft survival. Clin Transplant 6: 159-164
17. Daar AS 1995 Developments in immunosuppressive therapy. Transplant Proc 5: 2671-2675
18. Deng S, Brayman KL 1999 Gene therapy strategy to facilitate organ transplantation. Mol Med Today 5: 400-405
19. Dall'Amico R, Murer L, Montini G, Andreetta B, Zanon GF, Zacchello G, Zacchello F 1998 Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J Am Soc Nephrol 9: 121-127
20. Dunn JF, Hatch J, Precht A, Hart M, Li S 1996 Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared to azathioprine. Transplant Proc 28: 955-957
21. Dunn JF, Precht A, Hatch J et al 1995 Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared to azathioprine (abstract). Proceeding of International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis, pp 27-30
22. Duperray A, Languino L, Plescia J, McDowall A, Hogg N, Craig A, Berendt AR, Altieri DC 1997 Molecular identification of a novel fibrinogen binding on the first domain of ICAM-1-regulating leucocyte-endothelium bridging. J Biol Chem 272: 435-441
23. Elion GB 1993 The pharmacology of azathioprine. Ann NY Acad Sci 685: 401-407
24. European Mycophenolate Mofetil Cooperative Study Group 1995 Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroid for prevention of acute rejection. Lancet 345: 1321-1325
25. European Mycophenolate Mofetil Cooperative Study Group 1999 European mycophenolate mofetil trial: 3-year results. Transplantation 68: 391-396
26. Executive Summary. United Stales Renal Data System 1999 Annual Data Report 1999. Am J Kidney Dis 34: S9-S19
27. Figures from annual report on management of renal failure in Europe, XXVIII 1997 Presented at the XXXVth Congress of the European Renal Association-European Dialysis and Transplant Association. Rimini 1998
28. Friend PJ, Rebello P, Oliveira D, Manna D, Cobbold SP, Hale G, Jamieson NV et al 1995 Successful treatment of renal allograft rejection with a humanized anti-lymphocyte monoclonal antibody. Transplant Proc 27: 869-870
29. Fuggle S, Koo D 1998 Cell adhesion molecules in clinical renal transplantation. Transplantation 65: 763-769
30. Fuggle S, Sanderson J, Gray D, Richardson A, Morris P 1993 Variation expression of endothelial adhesion molecules in pretransplant and transplanted kidneys: Correlation with intragraft events. Transplantation 55: 610-615
31. Gaber LW, Moore LW, Gaber AO, Test RJ, Meyer J, Schroeder TJ 1999 Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report. Kidney Int 55: 241522-241524
32. Goodnow CC, Adelstein S, Basten A 1990 The need for central and peripheral tolerance in the B cell repertoire. Science 49: 273
33. Greene S, Watanabe K, Braatz-Trulson J, Lou L 1995 Inhibition of dihydrootate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50: 861-867
34. Grinyò J M, 1999 Mycophenolate-update after it has come of age. Nephrol Dial Transplant 14: 31-34
35. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL et al 1999 Sirolimus-(rapamycin) based therapy in human renal transplantation: similar efficacy and different toxicity, compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042
36. Gummert JF, Ikonen T, Morris RE 1999 Newer immunosuppressive drugs: A review. J Am Soc Nephrol 10: 1366-1380
37. Hamon MD, Gale RF, Mat-Donald ID, Smith OP, Collins CH, Skeggs DB, Gandhi L, Prentice HG 1993 Incidence of cataracts after a single fraction total body irradiation: the role of steroids and graft versus host disease. Bone Marrow Transplant 12: 233-236
38. Heldermann JH 1997 New immunologically non-specific immunosuppressive agents dictate changes in standard protocols for renal transplant management. Nephrol Dial Transplant 12 (Suppl 1): 51-54
39. Hill P, Main I, Atkins R 1995 ICAM-1 and VCAM-1 in human renal allograft rejection. Kidney Int 47: 1383-1391
40. Hodinka RL 1998 The clinical utility of viral quantitation using molecular methods. Clin Diagn Virol 10: 25-47
41. Hourmant M, Bedrossian J, Durand D, Kessler M, Le Brancha Y, Caudrelier P, Simi B, Soulillou JP 1995 Multicenter comparative study of an anti-LFA-1 adhesion molecule-monoclonal antobody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplant Proc 27: 864
42. Ierino FL, Gojo S, Banierjee PT, Giovino M, Xu Y, Gere J, Kaynor C et al 1999 Transfer of swine major histocompatibility complex class II genes into autologous bone marrow cell of baboons for the induction of tolerance across xenogeneic barriers. Transplantation 67: 1119-1128
43. Inaba K, Granelli PA, Steinman RM 1983 Dendritic cells induce T lymphocytes to release B cell-stimulating factors by an interleukin-2-dependent mechanism. J Exp Med 158: 2040
44. Ishikawa A, Itih M, Ushlyama T, Suzuki K, Fujita K 1998 Experience of ABO-incompatible living kidney transplantation after double filtration plasmapheresis. Clin Transplant 12: 80-83
45. June CH, Ledbetter JA, Linsley PS, Thompson CB 1990 Role of CD28 receptor in T-cell activation. Immunol Today 11: 211-216
46. Kaplan B, Meier-Kiersche HU, Jacobs MG, Friedman G, Bonomini L, De Franco P, Gelfand E, Mulgoankar S 1999 Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis 34: 65-68
47. Kaufman DB, Kim TH, Slavin S, Najarian JS, Sutherland DE 1989 Long-term clinical studies of high-risk renal retransplant recipients given total lymphoid irradiation. Transplant Proc 21: 1798-1799
48. Kawamura A, Osanai M, Yoneckawa 1998 Immunomodulation in transplant patients by cryofiltration. Ther Apher 2: 205-209
49. Kazimirov VG, Perlin DV, Shcherbakova EO, Prokopenko EI, Nesterenko IV 1998 Use of plasmapheresis in intensive therapy of acute steroid-resistant rejection reaction in renal transplants. Anesteziol Reanimato 6: 62-65
50. Kirbergh J, Swat W, Rocha B, Kisielow P, von Boehmer H 1993 Induction of tolerance in immature and mature T cells. Transplant Proc 25: 278-280
51. Kotb M, Russel WC, Hathaway DK, Gaber LW. Gaber AO 1999 The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients. Clin Transplant 13: 83-89
52. Kriaa F, Hiesse C, Alard P, Lantz O, Noury J, Charpentier B, Bazin H 1993 Prophylactic use of IL-2 receptor monoclonal antibody Lo-Tact 1 in cadaveric renal transplantation: result of a randomized study. Transplant Proc 25: 817-819
53. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR 1992 Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358: 70
54. Kuruvila CK, McCalmon RT, Schreiber DP, Kortz WJ 1997 Total lymphoid irradiation for pretransplant immunosuppression: nine year follow-up. Kidney Int Suppl 61: 89-92
55. Levin B, Hoppe RT, Collins G, Miller E, Waer M, Bieber C, Girinsky T, Strober S 1985 Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin and low-dose prednisone. Lancet 2: 1321-13
56. Liu J, Farmer JDJ, Lane WS, Friedman J, Weissman I, Scheiber SL 1991 Calcineunn is a common target of cyclophilin-cyclosporin A and FKB-FK506 complexes. Cell 66: 807
57. Locsey L, Asztalos L, Kineses Z, Berczi C, Paragh G 1998 The importance of obesity and hyperlipidaemia in patients with renal transplants. Int Urol Nephrol 30: 767-775
58. Lopes IM, Martin M, Errasti P, Martinez JA 1999 Benefit of dietary intervention on weight loss, body composition, and profile after renal transplantation. Nutrition 15: 7-10
59. Mahajan SK, Fisher KA, Simonian S, Hill JL, Katz AI, Stuart FP 1977 Selection of transplant candidates for splenectomy. Transplant Proc 9: 123-125
60. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, Palomaki GE et al 1990 The flow-cytometric crossmatch and early renal transplant loss. Transplantation 49: 527-535
61. Matherd TH 1998 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at three years. Transplantation 65: 1450-1454
62. McLaren AJ, Marshall SE, Haldar NA, Mullighan CG, Fuffle SV, Morris PJ, Welsh KI 1999 Adhesion molecule polymorphism in chronic renal allograft failure. Kidney Int 55: 1977-1982
63. Mercuriali F, Inghilleri G 1999 Transfusion risks and limitations. Minerva Anestesiol 65: 286-292
64. Mor E, Yussim A, Chodoff L, Schwartz ME 1997 New immunosuppressive agents for maintenence therapy in organ transplantation focus on adverse effects. Bio Drugs 8: 469-488
65. Moreso F, Seron D, Morales JM, Cruzado JM, Gil-Vernet S, Perez JL, Fulladosa X et at 1998 Incidence of leucopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 12: 198-205
66. Morris RE 1996 Mechanisms of action of new immunosuppressive drugs. Kidney Int Suppl 53: S26-38
67. Mourani C, Mallat S, Akatcherian C, Moussalli A 1998 Reversible severe vascular rejection after plasmapheresis. J Med Leban 46: 40-42
68. Myburgh JA, Meyers AM, Thomson PD, Botha JR, Margolius L, Lakier R, Smit JA, Stark JH, Gray C 1989 Total lymphoid in kidney transplantation. Trasplant Proc 21: 3953-3954
69. Najarian J, Ferguson RM, Sutherland DE, Slavin S, Kim T, Kersey J, Simmons RS 1982 Fractionated total lymphoid irradiation as preoperative immunosuppression in high risk renal transplantation: clinical and immunological studies. Ann Surg 196: 492-452
70. Nishikawa K, Shibasaki C, Takahashi K, Nakamura T, Takeuchi T, Umezawa H 1986 Antitumor activity of spergualin: a novel antitumor antibiotic. J Antibiot 39: 1461-1466
71. O'Malley KJ, Cook DJ, Roeske L, McCarthy JF, Klingman LL, Kapoor A, Hobart MG et al 1999 Acute rejection and flow cytometry crossmatch. Transplant Proc 31: 1216-1217
72. Ona Y, Ohshima S, Kinakawa T, Matsuura O, Hirabayashi S 1987 MRL suppression activity induced by thoracic duct drainage prior to transplantation. Transplant Proc 19: 1985-1987
73. Opelz G, Terasaki PI 1978 Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 299: 799
74. Opelz G, Terasaki PI 1973 Effect of splenectomy on human renal transplants. Transplantation 15: 605-608
75. Parlevliet KJ, Schellkens PT 1992 Monoclonal antibodies in renal transplantation: a review. Transplant Int 5: 234-246
76. Perico N, Remuzzi G 1997 Prevention of transplant rejection: Current treatment guidelines and future developments. Drugs 54: 533-570
77. Perotti C, Torretta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S, Del Fante C et al 1999 Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 84: 237-241
78. Peters GJ, Schwartsmann G, Nadal JC, Laurenesse EJ, van Groeningen CJ, van der Vijgh WJ, Pinedo HM 1990 In vivo inhibition of pyrimidine de-novo enzyme dehydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res 50: 4644-4649
79. Pober JS, Gimbrone MA, Cotran RS 1983 IA expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med 157: 1339
80. Punch DJ, Lin J, Bluestone J, Bromberg JS 1999 CD2 and CD3 receptor-mediated tolerance: Constraints on T cell activation. Transplantation 67: 741-748
81. Rubin RH 1994 Infection in the organ transplant recipients. In: Rubin RH, Young LS (eds) Clinical approach to infection in the compromised host (3rd ed). Plenum, New York, p 629
82. Sayegh M, Watschinger B, Carpenter C 1994 Mechanisms of T cell recognition of alloantigen: role of peptides. Transplantation 57: 1295-1302
83. Schmoeckel M, Bhatti FN, Zaidi A, Cozzi E, Chavez G, Wallwork J, White DJ, Friend PJ 1999 Splenectomy improves survival of HDAF-transgenic pig kidneys in primates. Transplant Proc 31: 961
84. Schroeder TJ, Moore LW, Gaber LW, Gaber AO, First MR 1999 The US multicenter double blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design. Transplant Proc 31 (3B Suppl): 1S-6S
85. Schwartz RH 1989 Acquisition of immunologic self-tolerance. Cell 57: 1073-1081
86. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group 1995 Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-232
87. Steinman R, Young J 1991 Signal arising from antigen-presenting cells. Curr Opin Immunol 3: 361-372
88. Sukhatme VP 1977 Gene therapy for kidney disease. Adv Nephrol Necker Hosp 26: 73-80
89. Suzuki S 1993 Deoxyspergualin: mode of action and clinical trials. Ann NY Acad Sci 696: 123-132
90. Takeuchi N, Ohshima S Ono Y, Sahashi M, Matsuura O, Yamada S, Tanaka K et al 1992 Five-year result of thoracic duct drainage in living related donor kidney transplantation. Transplant Proc 24: 1421-1423
91. Tarantino A, Aroldi A, Stucchi L, Montagnino G, Mascaretti L, Vegeto A, Ponticelli C 1991 A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation 52: 53-57
92. Taylor CJ, Chapman JR, Ting A, Morris PJ 1989 Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 48: 953-958
93. Tepper M 1993 Deoxyspergualin: mechanism of action of a novel immunosuppressive drug. Ann NY Acad Sci 696: 123-132
94. The Mycophenolate Mofetil Renal Refractory Rejection Study Group 1996 Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 61: 722-729
95. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group 1996 A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037
96. Thomas ME, Brunskill NJ, Harris KP, Bailey E, Pringle JH, Furness PN, Walls J 1999 Proteinuria indices tubular cell turnover: A potential mechanism for tubular atrophy. Kidney Int 55: 890-898
97. Thomson AW, Starzl TE 1993 New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 136: 71-98
98. Ting A 1983 The lymphocytotoxic crossmatch test in clinical transplantation. Transplantation 35: 403-407
99. Touchard G, Hauet T, Cogny Van Vaydevelt F, Hurault de Ligny B, Peyrronet P, Lebranchu Y et al 1997 Maintenance cyclosporin monotherapy after renal transplantation - clinical predictors of long-term outcome. Nephrol Dial Transplant 12: 1956-1960
100. Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB 1990 CD28 is an inducible Y cell surface antigen in CD3+ mature thymocytes. J Immunol 144: 1646-1653
101. US Renal Transplant Mycophenolate Mofetil Study Group 1999 Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 34: 296-303
102. Valenle JF, Alexander JW 1998 Immunobiology of renal transplantation. Surg Clin North Am 78: 1-26
103. van Gelder T, Hillbrands LB, Vanrenterghem Y, Weimar W, de Fijter SV, Squifflet JP, Hene RJ et al 1999 A randomized double-blind plasma concentration-controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Tansplantation 68: 261-266
104. van Seventer G, Shimuzu Y, Hogan K, Shaw S 1990 The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144: 4579-4586
105. Vanrenterghem Y 1997 The use of mycopenolate mofetil (Cellcept) in renal transplantation. Nephron 76: 392-399
106. von Villebrand E, Jurcic V, Isoniemi J, Hayry P, Paavonen T, Krogerus L 1997 Adhesion molecules and their ligands in chronic rejection of human renal allografts. Transplant Proc 29: 1530-1531
107. Waer M, Vanrenterghem Y, Ang KK, Van der Schueren E, Michielsen P, Vandeputte M 1984 Comparsion of the immunosuppressive effect of fractionated total lymphoid irradiation (TL1) vs conventional immunosuppression (CI) in renal cadaveric allotransplantation. J Immunol 132: 1041-1048
108. Wreghitt TG 1999 Blood-borne virus infections in dialysis units - a review. Rev Med Virol 9: 101-109
109. Vildiz A, Erkoç R, Sever MS, Tuerkmen A, Ecder ST, Tuerk S, Kiliçarlan I, Ark E 1999 The prognostic importance of severity and type of post-transplant proteinuria. Clin Transplant 13: 241-244
110. Zaoui P, Serre-Debeauvais G, Bayle F, Bessard G, Pintar P, Deteix P, Janbon B, Vialtel P 1995 Clinical use of mizoribin (Bredinin) and pharmacologic monitoring assessment in renal transplantation. Transplant Proc 27: 1064-1065
111. Zeier M, Mandelbaum A, Ritz E 1998 Hypertension in the transplanted patient. Nephron 80: 257-268